中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2015年
3期
322-325
,共4页
双黄升白颗粒%肝炎,丙型,慢性%抗病毒药%白细胞计数
雙黃升白顆粒%肝炎,丙型,慢性%抗病毒藥%白細胞計數
쌍황승백과립%간염,병형,만성%항병독약%백세포계수
Shuanghuang shengbai granule%Hepatitis C,chronic%Antiviral agents%Leukocyte count
目的:探讨双黄升白颗粒预防性治疗慢性丙型病毒性肝炎干扰素抗病毒治疗所致白细胞计数减少的临床疗效。方法选取2011年6月—2013年6月河南省中医院收治的慢性丙型病毒性肝炎患者62例,采用随机数字表法分为治疗组32例,对照组30例,分别于干扰素治疗开始同时服用双黄升白颗粒(15 g/次,3次/ d)和利血生(20 mg/次,3次/ d),然后检测每组患者治疗前,治疗后2、4、8周外周血白细胞计数、中性粒细胞计数及骨髓抑制情况。结果两组治疗前后白细胞计数和中性粒细胞计数比较,差异均有统计学意义(P ﹤0.05);治疗方法与治疗时间存在交互作用(P ﹤0.05);组间比较,差异有统计学意义(P ﹤0.05);时间间比较,差异有统计学意义( P ﹤0.05)。对照组22例(73.3%)患者发生骨髓抑制,其中轻度14例、中度6例、重度2例;治疗组12例(37.5%)患者发生骨髓抑制,其中轻度9例、中度2例、重度1例。对照组骨髓抑制发生率高于治疗组(χ2=10.980,P =0.011)。结论双黄升白颗粒预防性用药对于治疗干扰素所致白细胞计数减少较利血生效果好,同时所致骨髓抑制发生率更低,双黄升白颗粒是一种安全有效的预防干扰素所致白细胞计数减少的有效药物。
目的:探討雙黃升白顆粒預防性治療慢性丙型病毒性肝炎榦擾素抗病毒治療所緻白細胞計數減少的臨床療效。方法選取2011年6月—2013年6月河南省中醫院收治的慢性丙型病毒性肝炎患者62例,採用隨機數字錶法分為治療組32例,對照組30例,分彆于榦擾素治療開始同時服用雙黃升白顆粒(15 g/次,3次/ d)和利血生(20 mg/次,3次/ d),然後檢測每組患者治療前,治療後2、4、8週外週血白細胞計數、中性粒細胞計數及骨髓抑製情況。結果兩組治療前後白細胞計數和中性粒細胞計數比較,差異均有統計學意義(P ﹤0.05);治療方法與治療時間存在交互作用(P ﹤0.05);組間比較,差異有統計學意義(P ﹤0.05);時間間比較,差異有統計學意義( P ﹤0.05)。對照組22例(73.3%)患者髮生骨髓抑製,其中輕度14例、中度6例、重度2例;治療組12例(37.5%)患者髮生骨髓抑製,其中輕度9例、中度2例、重度1例。對照組骨髓抑製髮生率高于治療組(χ2=10.980,P =0.011)。結論雙黃升白顆粒預防性用藥對于治療榦擾素所緻白細胞計數減少較利血生效果好,同時所緻骨髓抑製髮生率更低,雙黃升白顆粒是一種安全有效的預防榦擾素所緻白細胞計數減少的有效藥物。
목적:탐토쌍황승백과립예방성치료만성병형병독성간염간우소항병독치료소치백세포계수감소적림상료효。방법선취2011년6월—2013년6월하남성중의원수치적만성병형병독성간염환자62례,채용수궤수자표법분위치료조32례,대조조30례,분별우간우소치료개시동시복용쌍황승백과립(15 g/차,3차/ d)화리혈생(20 mg/차,3차/ d),연후검측매조환자치료전,치료후2、4、8주외주혈백세포계수、중성립세포계수급골수억제정황。결과량조치료전후백세포계수화중성립세포계수비교,차이균유통계학의의(P ﹤0.05);치료방법여치료시간존재교호작용(P ﹤0.05);조간비교,차이유통계학의의(P ﹤0.05);시간간비교,차이유통계학의의( P ﹤0.05)。대조조22례(73.3%)환자발생골수억제,기중경도14례、중도6례、중도2례;치료조12례(37.5%)환자발생골수억제,기중경도9례、중도2례、중도1례。대조조골수억제발생솔고우치료조(χ2=10.980,P =0.011)。결론쌍황승백과립예방성용약대우치료간우소소치백세포계수감소교리혈생효과호,동시소치골수억제발생솔경저,쌍황승백과립시일충안전유효적예방간우소소치백세포계수감소적유효약물。
Objective To observe the effect of Shuanghuang Shengbai granule in preventive treatment for interferon induced leucopenia in patients with chronic hepatitis C. Methods 62 patients with chronic hepatitis C treated in Henan Traditional Chinese Medicine Hospital from June 2011 to June 2013 were randomly divided into treatment group(31 cases)and control group(30 cases). The two groups were given Shuanghuang Shengbai granule(15 g a time,three times per day)and Leucogen(20 mg a time,three times per day). The peripheral white blood cells count,neutrophil count and bone marrow suppression were detected before treatment,two weeks,four weeks and eight weeks after treatment. Results The white blood cells count and neutrophil count before and after treatment between the two groups both showed statistically significant differences (P ﹤ 0. 05). There was interaction between treatment and time( P ﹤ 0. 05). The inter - group difference was statistically significant(P ﹤ 0. 05),and the time showed statistically significant difference(P ﹤ 0. 05). 22 cases(73. 3% )in the control group had bone marrow suppression,with 14 slight level cases,6 moderate level cases and 2 severe level cases;12 cases (37. 5% )in the treatment group had bone marrow suppression,with 9 slight level cases,2 moderate level cases and one severe level case. The control group had higher incidence of bone marrow suppression than the treatment group( χ2 = 10. 980,P =0. 011). Conclusion Shuanghuang Shengbai granule has good effect with leucogen in preventing leukopenia induced by IFN, and it is a safe,cheap and convenient drug to treat leucopenia induced by IFN.